Kodiak Sciences Inc.
NASDAQ:KOD · NASDAQ Global Market
-$0.03 today
Vol 1.21M · Avg 1.10M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $169.5M |
| Other Current | $5.7M |
| Total Current Assets | $175.3M |
| PP&E (Net) | $115.9M |
| Long-term Investments | $6.2M |
| Other Non-current | $8.7M |
| Total Non-current Assets | $130.7M |
| Total Assets | $306.0M |
Analysis
Selected assets total $306.0M for Latest. The largest visible component is Cash & Equivalents at $169.5M, about 55.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $209.9M +24.9% | $168.1M -41.1% | $285.5M +49.9% | $190.4M -74.0% | $731.5M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 -100.0% | $288.5M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $0 | $0 | $0 | $0 | $0 | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 | $0 | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $5.0M +28.3% | $3.9M +1.6% | $3.8M -46.2% | $7.1M +114.2% | $3.3M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $214.8M +24.9% | $171.9M -40.6% | $289.3M -40.5% | $486.0M -33.9% | $734.8M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $121.9M -18.1% | $148.7M -15.0% | $175.0M +51.2% | $115.8M +7.1% | $108.1M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $6.2M +0.0% | $6.2M -2.2% | $6.3M +0.0% | $6.3M +0.0% | $6.3M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $8.7M -0.7% | $8.7M +0.1% | $8.7M -85.1% | $58.5M +6.4% | $55.0M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $136.7M -16.5% | $163.6M -13.9% | $190.1M +5.2% | $180.6M +6.6% | $169.4M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $351.5M +4.8% | $335.6M -30.0% | $479.4M -28.1% | $666.6M -26.3% | $904.2M | $13.3B | $11.9B | $10.6B |
| Account Payables | $12.9M +228.6% | $3.9M -71.2% | $13.6M +49.0% | $9.1M -26.6% | $12.4M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $12.1M | $0 -100.0% | $9.8M -1.6% | $9.9M +152.4% | $3.9M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $20.6M | $0 -100.0% | $12.3M -55.2% | $27.4M -34.9% | $42.1M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $45.5M +78.1% | $25.6M -38.7% | $41.7M -20.5% | $52.5M -18.8% | $64.7M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $100.0M | $0 -100.0% | $100.0M +0.0% | $100.0M +0.1% | $99.9M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $1.5M -98.5% | $100.0M | $0 -100.0% | $162.0K -23.2% | $211.0K | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $148.6M -6.9% | $159.7M -7.1% | $171.9M -3.4% | $178.0M +1.0% | $176.2M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $194.2M +4.8% | $185.3M -13.3% | $213.6M -7.3% | $230.5M -4.3% | $240.9M | $14.7B | $3.7B | $9.6B |
| Common Stock | $6.0K +20.0% | $5.0K +0.0% | $5.0K +0.0% | $5.0K +0.0% | $5.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$1.6B -17.3% | -$1.3B -15.3% | -$1.2B -29.2% | -$892.0M -59.8% | -$558.2M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 | $0 +100.0% | -$1.3M | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $157.4M +4.7% | $150.3M -43.5% | $265.8M -39.1% | $436.2M -34.2% | $663.3M | $9.1B | $7.7B | $3.3B |
| Total Debt | $159.2M +126.3% | $70.3M -61.3% | $181.6M -3.2% | $187.7M +4.3% | $179.9M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$50.7M +48.1% | -$97.7M +5.9% | -$103.9M -3741.5% | -$2.7M +99.5% | -$551.6M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
AnaptysBio, Inc.
NASDAQ:ANAB
$2.39B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.59B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.49B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.13B
Xencor, Inc.
NASDAQ:XNCR
$928.99M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$856.01M
Oculis Holding AG
NASDAQ:OCS
$636.87M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$610.02M
ProKidney Corp.
NASDAQ:PROK
$263.28M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does KOD have?
Kodiak Sciences Inc. (KOD) reported $209.86M in cash and equivalents in fiscal 2025.
How much debt does KOD carry?
Kodiak Sciences Inc. (KOD) reported $159.18M of total debt, with net debt of -$50,682,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.